Utilization of intravenous immunoglobulin therapy to treat recurrent pregnancy
loss in the antiphospholipid syndrome: a review.
Scand J Rheumatol Suppl 1998;107:97-102 (ISSN: 0301-3847)
Harris EN; Pierangeli SS
Academic Affairs, Morehouse School of Medicine, Atlanta, GA 30310-1495, USA.
Although experience is still limited, intravenous immunoglobulin therapy for
recurrent pregnancy loss in the Antiphospholipid Syndrome (APS) may represent a
significant advance. APS was widely recognized only fifteen years ago. Pregnancy
loss and thrombosis are the prominent clinical features. Initially, prednisone was
used for treatment of pregnancy loss, but matemal and fetal complications
stimulated searches for alternative therapy. Subcutaneous heparin and low dose
aspirin was next utilized, but although efficacious, there is still a 30% failure rate,
and intrauterine growth retardation, prematurity, and pre-eclampsia are relatively
frequent. In the late 1980's, there were a number of case reports of successful
pregnancy outcomes after treatment with intravenous immunoglobulin (IVIg) but
regimens differed. Series from two centers have confirmed these initial findings
and treatment regimens have become more consistent. Both centers have reported
success with doses of 400 mg/kg/day for 5 days or 1 g/kg/day for two days each
month initiated during the first or early second trimester. Success rates of 70-100%
have been reported, and complications such as pre-eclampsia, intrauterine growth
retardation, and premature births appear reduced, when compared to prednisone
and low dose aspirin or heparin and low dose aspirin. Several patients who were
treated with IVIg also received heparin, making it uncertain whether heparin may
also need to be added to IVIg. Intravenous immunoglobulin is safe, but expensive.
Despite its expense, if IVIG is shown to markedly decrease matemal and fetal
morbidity, it may be the logical treatment of choice to prevent pregnancy loss in
APS.
back next
print this page
If you value this service, kindly consider a donation to the Canadian Breastfeeding Foundation (registered charity) and earmark the donation for the Newman Breastfeeding Clinic and Institute and/or the Goldfarb Breastfeeding Program.
You can donate through their website, canadianbreastfeedingfoundation.org, or by mail to Canadian Breastfeeding Foundation, 5764 Monkland Ave, Suite 424, Montreal, Quebec, Canada, H4A 1E9.
Disclaimer: All material provided in asklenore.info is provided for educational purposes only. Consult your physician regarding the advisability of any opinions or recommendations with respect to your individual situation.
top